Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

Future COVID vaccines must be better; Science rushes to answer


David L. Hoey, President and CEO of Vaxxas, Cambridge, MA, and Brisbane, Australia.

Pablo Penaloza-MacMaster, PhD, Assistant Professor of Microbiology and Immunology, Feinberg School of Medicine, Northwestern University, Chicago.

Jasdave Chahal, PhD, Co-Founder and Chief Scientist, Tiba Biotech, Cambridge, MA, and Brisbane, Australia.

Vaxart press release: “Vaxart has announced positive first-line Phase II clinical study data demonstrating the safety and immunogenicity of its COVID-19 pill vaccine candidate only in Wuhan.”

Mark Herr, Spokesperson, Vaxart Inc.

The Commonwealth Fund: “Two years of US vaccines against COVID-19 have prevented millions of hospitalizations and deaths.”

The Lancet infectious diseases: “Global impact of the first year of vaccination against COVID-19: a mathematical modeling study.”

CDC: COVID Data Tracker, “Needle Fears and Phobias—Find Ways to Manage.”

US Specialty Formulations Press Release: “Research Demonstrates Benefits of Oral COVID-19 Vaccine.”

CanSino Biologics Inc. Statement: “Inside Information”.

Coalition for Epidemic Preparedness Innovations: Statement by e-mail; Press releases: “Future-proof race for coronavirus vaccines;.” “Coming in from the cold: Needle-free patch technology for mRNA vaccines aims to end the need for frozen storage and improve access.”

Executive Office of the President: “Statement of Administrative Policy”.

Science: “RBD mosaic nanoparticles protect against challenge by various sarbecoviruses in animal models.”

Caltech press release: “Nanoparticle vaccine protects against a spectrum of variants and viruses associated with the origin of COVID-19.”

US Government Accountability Office. “Operation Warp Speed.”

Bharat Biotech International Limited press release: “Bharat biotech launches iNCOVACC: the world’s first intranasal COVID vaccine for primary series and heterologous booster.”

The Lancet preprints: “Immunogenicity and Safety of BBV154 (iNCOVACC®), an Intranasal SARS-CoV-2 Vaccine, Compared to Intramuscular Covaxin® in Healthy Adults: A Randomized, Open-Label, Phase 3 Clinical Trial.”

Cell: “Paediatric intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.”

National Institute of Allergy and Infectious Diseases Press Release: “NIAID Issues New Awards to Support Pancoronavirus Vaccine Development.”

CEPI Press Release: “CEPI and DIOSynVax Partner to Develop Broadly Protective Vaccine Against Betacoronavirus.”

CDC: “Understanding how COVID-19 vaccines work”.

Natural immunology: “The T cell immune response against SARS-CoV-2.”

National Institutes of Health: “T cells protect against COVID-19 in the absence of an antibody response.”

PNAS: “Vaccine-induced systemic and mucosal T-cell immunity against SARS-CoV-2 viral variants.”

Cell reports: “Pre-existing immunity modulates responses to mRNA boosters.”

University of Minnesota Center for Infectious Disease Research and Policy: “Coronavirus Vaccine R&D Roadmap”.

NIH Press Release: “2NIAID Studies Highlight Potential of Natal COVID-10 Vaccine.”

US Specialty Formulations Press Release: “Research Demonstrates Benefits of Oral COVID-19 Vaccine. »

webmd Gt

Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button